Back to top
more

RxSight (RXST)

(Delayed Data from NSDQ)

$51.25 USD

51.25
570,679

+0.15 (0.29%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $51.30 +0.05 (0.10%) 5:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?

The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2

RxSight (RXST) delivered earnings and revenue surprises of 100% and 8.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround

RxSight (RXST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for RxSight (RXST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

What Makes RxSight, Inc. (RXST) a Strong Momentum Stock: Buy Now?

Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Nalak Das headshot

Buy 5 Medical Instruments Stocks to Enhance Your Portfolio

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

Smart Beta ETF report for FYC

What's in the Offing for Brainsway (BWAY) in Q4 Earnings?

Brainsway's (BWAY) fourth-quarter 2023 performance is likely to have been impacted by the strong momentum across the entire business.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

Smart Beta ETF report for XHE

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

Sector ETF report for XHE

Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?

Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.

Charles River (CRL) to Report Q4 Earnings: What's in Store?

The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.

IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store?

Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4.

What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?

Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q4 Earnings?

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?

CVS Health's (CVS) fourth-quarter 2023 results are likely to reflect the strength of the Pharmacy & Consumer Wellness and Health Services segments.

What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?

Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.

Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store?

Quest Diagnostics' (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.

What's in Store for Boston Scientific (BSX) in Q4 Earnings?

Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

Align Technology's (ALGN) fourth-quarter 2023 results are likely to reflect the strength of the Clear Aligner and Systems & Services businesses.

Strength Seen in Integer (ITGR): Can Its 3.8% Jump Turn into More Strength?

Integer (ITGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

RxSight, Inc. (RXST) Just Overtook the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

RxSight, Inc. (RXST) Recently Broke Out Above the 50-Day Moving Average

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

RxSight, Inc. (RXST) Crossed Above the 20-Day Moving Average: What That Means for Investors

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?